Secondary Prevention Medications Post Coronary Artery Bypass Grafting Surgery-A Literature Review
Secondary prevention after coronary artery bypass graft (CABG) surgery is imperative in slowing the progression of atherosclerosis in both native and grafted vessels. Aspirin and statins remain the key medications for all patients without significant contraindications. The evidence for dual antiplatelet therapy with clopidogrel is less convincing, but there is hope for newer antiplatelet agents, such as ticagrelor. Meanwhile, β-blockers and angiotensin converting enzyme inhibitors might only offer benefits to specific sub-groups. Post-CABG patients appear to have different medication needs to the general cardiovascular patient and respond differently. In this review, we cover the drug regimens proposed by recent guidelines and the evidence behind their use. Assessing the evidence behind these recommendations, we find that there is an unmet need in some areas for robust population-specific evidence. We hope that future research will address this gap.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Journal of cardiovascular pharmacology and therapeutics - 26(2021), 4 vom: 15. Juli, Seite 310-320 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dimitriadis, Stavros [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.01.2022 Date Revised 14.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1074248420987445 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320757374 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320757374 | ||
| 003 | DE-627 | ||
| 005 | 20231225174257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1074248420987445 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320757374 | ||
| 035 | |a (NLM)33514291 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dimitriadis, Stavros |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Secondary Prevention Medications Post Coronary Artery Bypass Grafting Surgery-A Literature Review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.01.2022 | ||
| 500 | |a Date Revised 14.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Secondary prevention after coronary artery bypass graft (CABG) surgery is imperative in slowing the progression of atherosclerosis in both native and grafted vessels. Aspirin and statins remain the key medications for all patients without significant contraindications. The evidence for dual antiplatelet therapy with clopidogrel is less convincing, but there is hope for newer antiplatelet agents, such as ticagrelor. Meanwhile, β-blockers and angiotensin converting enzyme inhibitors might only offer benefits to specific sub-groups. Post-CABG patients appear to have different medication needs to the general cardiovascular patient and respond differently. In this review, we cover the drug regimens proposed by recent guidelines and the evidence behind their use. Assessing the evidence behind these recommendations, we find that there is an unmet need in some areas for robust population-specific evidence. We hope that future research will address this gap | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CABG | |
| 650 | 4 | |a antiplatelets | |
| 650 | 4 | |a secondary prevention | |
| 650 | 4 | |a statins | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Purinergic P2Y Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Qian, Evelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Irvine, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Harky, Amer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular pharmacology and therapeutics |d 1996 |g 26(2021), 4 vom: 15. Juli, Seite 310-320 |w (DE-627)NLM095431454 |x 1940-4034 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:4 |g day:15 |g month:07 |g pages:310-320 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1074248420987445 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 4 |b 15 |c 07 |h 310-320 | ||